COVID-19 PrEP HCW HCQ Study

Belmont et al., ClinicalTrials.gov, NCT04354870, NCT04354870

Oct 2021

Source PDF All Studies Meta AnalysisMeta

Prospective study of HCQ prophylaxis in the USA, with 56 HCQ patients and 24 control patients, showing no significant differences. NCT04354870 (history)

Important missing comments or errors? Let us know.

risk of symptomatic case, 78.6% lower, RR 0.21, p = 0.21, treatment 1 of 56 (1.8%), control 2 of 24 (8.3%), NNT 15.

risk of case, 14.3% lower, RR 0.86, p = 1.00, treatment 4 of 56 (7.1%), control 2 of 24 (8.3%), NNT 84.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Belmont et al., 6 Oct 2021, prospective, USA, preprint, 1 author, trial NCT04354870 (history).

All Studies Meta Analysis Submit Updates or Corrections

This Paper HCQ All

Download Image

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

@CovidAnalysis

FAQ

Public domain CC0 1.0